The estimated Net Worth of William B. Iii Stilley is at least $685 Tisíc dollars as of 29 November 2021. Mr. Stilley owns over 20,600 units of Avalon GloboCare Corp stock worth over $496,952 and over the last 6 years he sold AVCO stock worth over $0. In addition, he makes $188,412 as Independent Director at Avalon GloboCare Corp.
William has made over 3 trades of the Avalon GloboCare Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 20,600 units of AVCO stock worth $55,002 on 29 November 2021.
The largest trade he's ever made was buying 80,000 units of Avalon GloboCare Corp stock on 31 July 2018 worth over $42,400. On average, William trades about 9,662 units every 94 days since 2018. As of 29 November 2021 he still owns at least 937,646 units of Avalon GloboCare Corp stock.
You can see the complete history of Mr. Stilley stock trades at the bottom of the page.
William B. Stilley III serves as Independent Director of the Company. Mr. Stilley has been the chief executive officer and member of the board of directors of Adial Pharmaceuticals, Inc. since December 2010. From August 2008 until December 2010, he was the vice president, business development and strategic projects at Clinical Data, Inc. (NASDQ: CLDA). From February 2002, Mr. Stilley was the COO and CFO of Adenosine Therapeutics, LLC until certain assets of Adenosine Therapeutics were acquired by Clinical Data, Inc. in August 2008. Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public company, the interim Chief Business Officer of Diffusion Pharmaceuticals from September 2015 through December 2015, and the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He currently serves on the Board of Virginia BIO, the statewide biotechnology organization. Mr. Stilley is qualified to serve as a director because of his extensive knowledge of the biotechnology industry, significant executive leadership and operational experience, and knowledge of, and experience in, financing and M&A transactions.
As the Independent Director of Avalon GloboCare Corp, the total compensation of William Stilley at Avalon GloboCare Corp is $188,412. There are 9 executives at Avalon GloboCare Corp getting paid more, with Lu Wenzhao having the highest compensation of $4,047,220.
William Stilley is 52, he's been the Independent Director of Avalon GloboCare Corp since 2018. There are 5 older and 4 younger executives at Avalon GloboCare Corp. The oldest executive at Avalon GloboCare Corp is Wilbert Tauzin, 76, who is the Director.
William's mailing address filed with the SEC is 1180 SEMINOLE TRAIL, SUITE 495, , CHARLOTTESVILLE,, VA, 22901.
Over the last 8 years, insiders at Avalon GloboCare Corp have traded over $2,500,000 worth of Avalon GloboCare Corp stock and bought 898,876 units worth $1,418,962 . The most active insiders traders include Wenzhao Lu, Luisa Ingargiola a Steven Andrew Sanders. On average, Avalon GloboCare Corp executives and independent directors trade stock every 157 days with the average trade being worth of $446,629. The most recent stock trade was executed by Wenzhao Lu on 1 April 2020, trading 645,161 units of AVCO stock currently worth $1,000,000.
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare Corp executives and other stock owners filed with the SEC include: